Диссертация (1155054), страница 33
Текст из файла (страница 33)
Kaposi’s sarcoma in children: An open randomised trial of vincristine, oraletoposide and a combination of vincristine and bleomycin / G. Chagaluka, C. Stanley,K. Banda [et al.] // European Journal of Cancer. – 2014. – Vol. 50. – № 8. – P. 14721481 doi:10.1016/j.ejca.2014.02.019.135. Karanth H. pH-Sensitive liposomes-principle and application in cancer therapy /H. Karanth, R.S.R. Murthy // Journal of Pharmacy and Pharmacology.
– 2007. –Vol. 59. – № 4. – P. 469-483 doi:10.1211/jpp.59.4.0001.136. Kivisto K. The role of human cytochrome P450 enzymes in the metabolism ofanticancer agents: implications for drug interactions. / K. Kivisto, H. Kroemer, M.Eichelbaum // British Journal of Clinical Pharmacology. – 1995. – Vol. 40. – № 6.
–P. 523-530 doi:10.1111/j.1365-2125.1995.tb05796.x.201137. Kumar A. Resealed Erythrocytes as a Carrier for Drug Targeting: A / A. Kumar,M. Verma, K. Jha // Thepharmajournal.Com. – 2011. – Vol. 3. – № 2. – P. 550-565.138. Kuntebommanahalli N Thimmaiah. Chemical Characterization of theDegradation Products of Vinblastine Dihydrogen Sulfate / Kuntebommanahalli NThimmaiah, V.S.
Sethi // Cancer Research. – 1985. – Vol. 45. – № November. –P. 5382-5385.139. Langone J.J. Radioimmunoassays for the vinca alkaloids, vinblastine andvincristine / J.J. Langone, M.R. D’Onofrio, H. Van Vunakis // AnalyticalBiochemistry. – 1979. – Vol.
95. – № 1. – P. 214-221 doi:10.1016/00032697(79)90208-2.140. Lee Y. Stimuli-responsive liposomes for drug delivery / Y. Lee, D.H. Thompson// Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. – 2017. –Vol. 9. – № 5. – P. e1450 doi:10.1002/wnan.1450.141. Levêque D. Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids / D.Levêque, F. Jehl // The Journal of Clinical Pharmacology. – 2007. – Vol.
47. – № 5. –P. 579-588 doi:10.1177/0091270007299430.142. Liposomal Vincristine Preparations Which Exhibit Decreased Drug Toxicity andIncreased Activity against Murine L1210 and P388 Tumors / L.D. Mayer, M.B. Bally,H. Loughrey [et al.] // Cancer Research. – 1990. – Vol. 50. – № 3. – P. 575-579.143. Liposome: classification, preparation, and applications / A. Akbarzadeh, R.Rezaei-Sadabady, S. Davaran [et al.] // Nanoscale Research Letters. – 2013. – Vol.
8. –№ 1. – P. 102 doi:10.1186/1556-276X-8-102.144. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) showprolonged circulation half-lives in vivo / T.M. Allen, C. Hansen, F. Martin [et al.] //Biochimica et Biophysica Acta (BBA) - Biomembranes.
– 1991. – Vol. 1066. – № 1. –P. 29-36 doi:10.1016/0005-2736(91)90246-5.145. Liu J. The Evolution of Microtubule End-Binding Protein 1 (EB1) and Roles in202Regulating Microtubule Behavior / J. Liu, R. Han // American Journal of PlantSciences. – 2015. – Vol. 06. – № 13. – P. 2114-2121 doi:10.4236/ajps.2015.613212.146. Lobert S. Interaction of Vinca Alkaloids with Tubulin: A Comparison ofVinblastine, Vincristine, and Vinorelbine / S. Lobert, B. Vulevic, J.J. Correia //Biochemistry. – 1996. – Vol.
35. – № 21. – P. 6806-6814 doi:10.1021/bi953037i.147. Magnani M. The Use of Resealed Erythrocytes as Carriers and Bioreactors :Advances in Experimental Medicine and Biology. Vol. 326 / M. Magnani, lohn R.DeLoach; eds. M. Magnani, J.R. DeLoach. – Boston, MA: Springer US, 1992. – 341 p.doi:10.1007/978-1-4615-3030-5.148. Magnani M. Erythrocyte Engineering for Drug Delivery and Targeting / M.Magnani, R.
Landes Company; ed. M. Magnani. – Texas, U.S.A.: Eurekah.com, 2002.– 151 p.149. Magnani M. Approaches to erythrocyte-mediated drug delivery / M. Magnani, L.Rossi // Expert Opinion on Drug Delivery. – 2014. – Vol. 11. – № 5. – P. 677-687doi:10.1517/17425247.2014.889679.150. Magnetic nanoparticles and targeted drug delivering / J. Chomoucka, J.Drbohlavova, D. Huska [et al.] // Pharmacological Research.
– 2010. – Vol. 62. – № 2.– P. 144-149 doi:10.1016/j.phrs.2010.01.014.151. Manfred Schwab. Encyclopedia of Cancer. Vol. 1. Encycl. Cancer / ManfredSchwab; ed. M. Schwab. – Verlag Berlin Heidelberg New York: Springer-VerlagBerlin Heidelberg New York, 2008. – 3236 p.152. Marsden N.V.B. Accumulation of Dextran in Human Red Cells after Hæmolysis /N.V.B. Marsden, S.G. Östling // Nature. – 1959. – Vol.
184. – № 4687. – P. 723-724doi:10.1038/184723a0.153. Mechanism of mitotic block and inhibition of cell proliferation by thesemisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. / V.K.Ngan, K. Bellman, B.T. Hill [et al.] // Molecular pharmacology. – 2001. – Vol. 60. –203№ 1. – P. 225-32 doi:10.1124/mol.60.1.225.154. Medicinal Plants. Med. Plants / P.P. Joy [et al.].
– Kerala: Kerala agriculturaluniversity, 1998. – 211 p.155. Microtubule-targeted agents: When mitochondria become essential tochemotherapy / A. Rovini, A. Savry, D. Braguer [et al.] // Biochimica et BiophysicaActa (BBA) - Bioenergetics. – 2011. – Vol. 1807. – № 6. – P. 679-688doi:10.1016/j.bbabio.2011.01.001.156. Mikstacka R.
Tubulin-interactive stilbene derivatives as anticancer agents / R.Mikstacka, T. Stefański, J. Różański // Cellular and Molecular Biology Letters. –2013. – Vol. 18. – № 3. – P. 368-97 doi:10.2478/s11658-013-0094-z.157. Missailidis S. anticancer-therapeutics / S. Missailidis; ed. S. Missailidis. – WestSussex: A John Wiley & Sons, Ltd., Publication, 2008. – 410 p.158. Modifications on the Basic Skeletons of Vinblastine and Vincristine / P.Keglevich, L. Hazai, G. Kalaus [et al.] // Molecules. – 2012.
– Vol. 17. – № 12. –P. 5893-5914 doi:10.3390/molecules17055893.159. Mohammadgholi A. Mechanism of the Interaction of Plant Alkaloid Vincristinewith DNA and Chromatin: Spectroscopic Study / A. Mohammadgholi, A. RabbaniChadegani, S. Fallah // DNA and Cell Biology. – 2013. – Vol. 32. – № 5. – P. 228-235doi:10.1089/dna.2012.1886.160. Moore A. Vincristine: Can its therapeutic index be enhanced? / A. Moore, R.Pinkerton // Pediatric Blood & Cancer.
– 2009. – Vol. 53. – № 7. – P. 1180-1187doi:10.1002/pbc.22161.161. Mosior M. The effect of ATP on the order and the mobility of lipids in the bovineerythrocyte membrane / M. Mosior, A. Mikołajczak, J. Gomułkiewicz // Biochimica etBiophysica Acta (BBA) - Biomembranes.
– 1990. – Vol. 1022. – № 3. – P. 361-364doi:10.1016/0005-2736(90)90286-W.162. Multifunctional nanoassemblies for vincristine sulfate delivery to overcome204multidrug resistance by escaping P-glycoprotein mediated efflux / P. Zhang, G. Ling,J. Sun [et al.] // Biomaterials. – 2011. – Vol. 32.
– № 23. – P. 5524-5533doi:10.1016/j.biomaterials.2011.04.022.163. Multifunctional Nanoparticles as Nanocarrier for Vincristine Sulfate Delivery ToOvercome Tumor Multidrug Resistance / Y. Wang, L. Dou, H. He [et al.] // MolecularPharmaceutics. – 2014. – Vol. 11. – № 3. – P. 885-894 doi:10.1021/mp400547u.164. Multifunctional targeting vinorelbine plus tetrandrine liposomes for treating brainglioma along with eliminating glioma stem cells / X. Li, W. Tang, Y. Jiang [et al.] //Oncotarget. – 2016.
– Vol. 7. – № 17. – P. 24604-24622.165. Muthulakshmi S. Influence of IAA on the vincristine content of Catharanthusroseus ( L ). G . Don . / S. Muthulakshmi, V. Pandiyarajan // Asian Journal of PlantScience and Research. – 2013. – Vol. 3. – № 4. – P. 81-87.166. Muzykantov V.R. Drug delivery by red blood cells: vascular carriers designed bymother nature / V.R.
Muzykantov // Expert Opinion on Drug Delivery. – 2010. –Vol. 7. – № 4. – P. 403-427 doi:10.1517/17425241003610633.167. Naeem M. Catharanthus roseus:Current Research and Future Prospects / M.Naeem, T. Aftab, M.M.A. Khan; eds. M. Naeem, T. Aftab, M.M.A. Khan. – Cham:Springer International Publishing, 2017. – 412 p. doi:10.1007/978-3-319-51620-2.168. Nangare K.A. Nanoerythrosomes: Engineered Erythrocytes as a Novel Carrier forthe Targeted Drug Delivery / K.A. Nangare, S.D.
Powar, S.A. Payghan // AsianJournal of Pharmaceutics. – 2016. – Vol. 10. – № 3. – P. s231-233.169. Nano-Oncology: Clinical Application for Cancer Therapy and FuturePerspectives / C. Riggio, E. Pagni, V. Raffa [et al.] // Journal of Nanomaterials. –2011. – Vol. 2011. – P. 1-10 doi:10.1155/2011/164506.170. Nanocarriers as an emerging platform for cancer therapy / D. Peer, J.M. Karp, S.Hong [et al.] // Nature Nanotechnology. – 2007. – Vol.
2. – № 12. – P. 751-760doi:10.1038/nnano.2007.387.205171. Nanoemulsion: Concepts, development and applications in drug delivery / Y.Singh, J.G. Meher, K. Raval [et al.] // Journal of Controlled Release. – 2017. –Vol. 252. – P. 28-49 doi:10.1016/j.jconrel.2017.03.008.172. Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress andChallenges / A. Babu, A.K. Templeton, A.
Munshi [et al.] // Journal of Nanomaterials.– 2013. – Vol. 2013. – P. 1-11 doi:10.1155/2013/863951.173. Nanotechnology in Drug Delivery / M. Ochubiojo, I. Chinwude, E. Ibanga [et al.]// Recent Advances in Novel Drug Carrier Systems / ed. A.D.
Sezer. – Rijeka, Croatia:InTech, 2012. – Nanotechnol. Drug Deliv. – P. 69-106 doi:10.5772/51384.174. National Institute for Health Research (NIHR) Horizon Scanning Centre.Erythrocyte encapsulated asparaginase ( GRASPA ) for acute lymphoblastic leukaemia– second line / National Institute for Health Research (NIHR) Horizon ScanningCentre. – 2015. – 1-9 p.175. Nicole C. The Vinca Alkaloids / C.
Nicole, L. Farnaes // Cancer Management inMan: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures /ed. B. R.Minev. – Dordrecht: Springer Science, 2011. – P. 521.176. Niemirowicz K. Nanocarriers in modern drug delivery systems / K. Niemirowicz,H.
Car // Chemik. – 2012. – Vol. 66. – № 8. – P. 875-881.177. Niosome Encapsulated of Vincristine Sulfate: Improved Anticancer Activity withReduced Toxicity in Mice / G. Parthasarathi, N. Udupa, P. Umadevi [et al.] // JournalofDrugTargeting.–1994.–Vol. 2.–№ 2.–P. 173-182doi:10.3109/10611869409015907.178. Nogales E. Electron Crystallography : NATO Science Series II: Mathematics,Physics and Chemistry.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
